Targeted therapies represent a major breakthrough in the treatment of adult acute lymphoblastic leukaemia (ALL). Because lymphoblastic leukaemia cells express a variety of specific antigens, those ones can serve as targets for monoclonal antibodies (MoAbs). Anti‐CD20 (rituximab), anti‐CD19 (blinatumomab, SAR3419), anti‐CD22 (epratuzumab, inotuzumab ozogamicin) and anti‐CD52 (alemtuzumab) have therefore been developed. Possible strategies even include recruitment of CD3 cytotoxic T cells (blinatumomab) or adoptive T‐cell therapy by gene transfer of CD19‐chimeric antigen receptors (CD19‐CARs). Recent data show that antibody‐based therapy is a highly promising treatment approach. However, optimal treatment approach still needs to be defined.